Latest Astellas Pharma Inc (ALPMY) Headlines
Was Medivation's Quarter a Disaster?
Todd Campbell, The Motley Fool - Motley Fool - Mon Mar 03, 5:30PM CST
Medivation's sell-off last week reflects investor disappointment in guidance for sales of Xtandi, a prostate cancer drug prescribed to patients who fail to respond to chemotherapy. Sales of Xtandi jumped double digit percentages...
Medivation Swings to Earnings in Q4 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 28, 8:30AM CST
Xtandi's approval in the pre-chemo setting would boost sales significantly.
Biotech Stock Roundup: Regeneron's Eylea Impresses, Gilead Files for Next HCV Drug - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Feb 19, 8:27AM CST
The Medicines Co. was also in the news with an FDA advisory panel refusing to back the company's antiplatelet agent, Cangrelor.
Primco Files Preliminary Form 14c to Increase Authorized Shares
PR Newswire - Tue Feb 18, 11:30PM CST
Primco Management Inc. (OTCQB: PMCM), a fully integrated multi-media entertainment and real estate development company today announced that the Company has filed Form 14c, as required by the Securities and Exchange Commission, informing shareholders of an increase in the authorized to 25 billion common shares as a reserve requirement for possible future conversion issuances, in accordance with contractual obligations to convertible debt holders based on the recent low stock price of $0.0001. The increase will further allow Primco to have sufficient shares available for equity funding, and/or for potential acquisitions which the Board of Directors may determine is in the best interest of the shareholders.
AVEO/Astellas Terminate Agreement - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 18, 3:30PM CST
AVEO Pharma and Astellas announced their decision to terminate their agreement for the development and commercialization of tivozanib.
Vical Q4 Loss Narrows - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 13, 11:10AM CST
Vical's fourth quarter loss narrows
Announcement of Intention to Privatize and Invitation to Express Interest
PR Newswire - Thu Feb 13, 4:31AM CST
The Government of the Republic of Chad formally announces its intention to partially privatize the Société des Télécommunications du Tchad ("Groupe SOTEL Tchad") pursuant to the terms of law 004/PR/96. The Ministry of Commerce and Industry hereby invites interested parties to express interest to acquire a majority of the shares of SOTEL
Cytokinetics Rises on Q4 Earnings Beat - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 10, 10:00AM CST
Cytokinetics reported fourth quarter 2013 earnings of 21 cents.
AVEO/Astellas Terminate Tivozanib Trial - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 31, 4:10PM CST
AVEO Pharmaceuticals and partner Astellas Pharma announced their decision to discontinue a phase II study evaluating tivozanib in patients suffering from locally recurrent or metastatic triple negative breast cancer.
Medivation Prevails in PREVAIL Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 29, 12:50PM CST
Medivation and Astellas intend to file for regulatory approval for the pre-chemo population shortly.
Early 2014 Advancing Companies with Expansion & New Distribution Opportunities: RiceBran, Whole Foods, Hain Celestial, DryShips and Chelsea Therapeutics
PR Newswire - Thu Jan 16, 8:05AM CST
News updates for NASDAQ companies making strides with financial results, new agreements & distribution opportunities: RiceBran Technologies (NASDAQ: RIBT), Whole Foods Market Inc. (NASDAQ: WFM), The Hain Celestial Group, Inc. (NASDAQ: HAIN), DryShips, Inc. (NASDAQ: DRYS) and Chelsea Therapeutics International Ltd. (NASDAQ: CHTP)
AVEO Falls on Tivozanib News - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 16, 4:20PM CST
AVEO Pharmaceuticals announced that data from a planned interim analysis of the phase II BATON study on tivozanib showed that the study is unlikely to meet the primary endpoint.
3 Investing Lessons From Dendreon
Leo Sun, The Motley Fool - Motley Fool - Wed Dec 04, 3:41PM CST
The fall of Dendreon is a grim cautionary tale for biotech investors. The stock has fallen more than 40% year to date, and is down more than 90% since its peak in 2010. Wall Street had believed that Dendreon's only marketed...
Medivation Q3 Loss Narrower Than Expected - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 13, 7:10AM CST
Xtandi U.S. net sales are expected to surpass the earlier guidance of $345-$365 million.
AVEO Q3 Loss Wider than Expected, Shares Down - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 12, 7:30AM CST
AVEO Pharmaceuticals reported third quarter 2013 loss of 47 cents per share.
Medivation Soars on Positive Xtandi Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 23, 3:00PM CDT
Medivation's share price shot up 8.2% on Oct 22, 2013 to close the trading session at $53.89.
Can an EU Approval Save This Dying Biotech?
Leo Sun, The Motley Fool - Motley Fool - Thu Sep 19, 9:29AM CDT
Dendreon is one of the most well-known cautionary tales of hype and broken promises in the biotech industry. In April 2010, the stock hit an all-time high of $54 per share after the company's prostate cancer drug Provenge was approved by the Food...
Astellas to Host Executive Women's Day at 2013 TOUR Championship by Coca-Cola
PR Newswire - Tue Sep 17, 6:30AM CDT
The PGA TOUR and Astellas Pharma US, Inc. ("Astellas"), a U.S. subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503), will host their 17th Astellas Presents Executive Women's Day, a day-long forum focusing on professional, health-related and personal development discussions, at the 2013 TOUR Championship by Coca-Cola in Atlanta. The event is part of the PGA TOUR's Women's Initiative and is the final Executive Women's Day program in the 2013 season.
Humana Downgraded to Neutral - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 05, 4:05PM CDT
On Sep 4, 2013, we downgraded our recommendation on Humana Inc. to Neutral from Outperform.
Astellas and Merck Collaborate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 04, 4:00PM CDT
Astellas Pharma joined forces with Merck for the co-promotion of its SGLT2 inhibitor, ipragliflozin (ASP1941)
Was Medivation's Quarter a Disaster?
Todd Campbell, The Motley Fool - Motley Fool - Mon Mar 03, 5:30PM CST
Medivation's sell-off last week reflects investor disappointment in guidance for sales of Xtandi, a prostate cancer drug prescribed to patients who fail to respond to chemotherapy. Sales of Xtandi jumped double digit percentages...
Medivation Swings to Earnings in Q4 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 28, 8:30AM CST
Xtandi's approval in the pre-chemo setting would boost sales significantly.
Biotech Stock Roundup: Regeneron's Eylea Impresses, Gilead Files for Next HCV Drug - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Feb 19, 8:27AM CST
The Medicines Co. was also in the news with an FDA advisory panel refusing to back the company's antiplatelet agent, Cangrelor.
Primco Files Preliminary Form 14c to Increase Authorized Shares
PR Newswire - Tue Feb 18, 11:30PM CST
Primco Management Inc. (OTCQB: PMCM), a fully integrated multi-media entertainment and real estate development company today announced that the Company has filed Form 14c, as required by the Securities and Exchange Commission, informing shareholders of an increase in the authorized to 25 billion common shares as a reserve requirement for possible future conversion issuances, in accordance with contractual obligations to convertible debt holders based on the recent low stock price of $0.0001. The increase will further allow Primco to have sufficient shares available for equity funding, and/or for potential acquisitions which the Board of Directors may determine is in the best interest of the shareholders.
AVEO/Astellas Terminate Agreement - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 18, 3:30PM CST
AVEO Pharma and Astellas announced their decision to terminate their agreement for the development and commercialization of tivozanib.
Vical Q4 Loss Narrows - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 13, 11:10AM CST
Vical's fourth quarter loss narrows
Announcement of Intention to Privatize and Invitation to Express Interest
PR Newswire - Thu Feb 13, 4:31AM CST
The Government of the Republic of Chad formally announces its intention to partially privatize the Société des Télécommunications du Tchad ("Groupe SOTEL Tchad") pursuant to the terms of law 004/PR/96. The Ministry of Commerce and Industry hereby invites interested parties to express interest to acquire a majority of the shares of SOTEL
Cytokinetics Rises on Q4 Earnings Beat - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 10, 10:00AM CST
Cytokinetics reported fourth quarter 2013 earnings of 21 cents.
AVEO/Astellas Terminate Tivozanib Trial - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jan 31, 4:10PM CST
AVEO Pharmaceuticals and partner Astellas Pharma announced their decision to discontinue a phase II study evaluating tivozanib in patients suffering from locally recurrent or metastatic triple negative breast cancer.
Medivation Prevails in PREVAIL Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jan 29, 12:50PM CST
Medivation and Astellas intend to file for regulatory approval for the pre-chemo population shortly.
Early 2014 Advancing Companies with Expansion & New Distribution Opportunities: RiceBran, Whole Foods, Hain Celestial, DryShips and Chelsea Therapeutics
PR Newswire - Thu Jan 16, 8:05AM CST
News updates for NASDAQ companies making strides with financial results, new agreements & distribution opportunities: RiceBran Technologies (NASDAQ: RIBT), Whole Foods Market Inc. (NASDAQ: WFM), The Hain Celestial Group, Inc. (NASDAQ: HAIN), DryShips, Inc. (NASDAQ: DRYS) and Chelsea Therapeutics International Ltd. (NASDAQ: CHTP)
AVEO Falls on Tivozanib News - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 16, 4:20PM CST
AVEO Pharmaceuticals announced that data from a planned interim analysis of the phase II BATON study on tivozanib showed that the study is unlikely to meet the primary endpoint.
3 Investing Lessons From Dendreon
Leo Sun, The Motley Fool - Motley Fool - Wed Dec 04, 3:41PM CST
The fall of Dendreon is a grim cautionary tale for biotech investors. The stock has fallen more than 40% year to date, and is down more than 90% since its peak in 2010. Wall Street had believed that Dendreon's only marketed...
Medivation Q3 Loss Narrower Than Expected - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 13, 7:10AM CST
Xtandi U.S. net sales are expected to surpass the earlier guidance of $345-$365 million.
AVEO Q3 Loss Wider than Expected, Shares Down - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 12, 7:30AM CST
AVEO Pharmaceuticals reported third quarter 2013 loss of 47 cents per share.
Medivation Soars on Positive Xtandi Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 23, 3:00PM CDT
Medivation's share price shot up 8.2% on Oct 22, 2013 to close the trading session at $53.89.
Can an EU Approval Save This Dying Biotech?
Leo Sun, The Motley Fool - Motley Fool - Thu Sep 19, 9:29AM CDT
Dendreon is one of the most well-known cautionary tales of hype and broken promises in the biotech industry. In April 2010, the stock hit an all-time high of $54 per share after the company's prostate cancer drug Provenge was approved by the Food...
Astellas to Host Executive Women's Day at 2013 TOUR Championship by Coca-Cola
PR Newswire - Tue Sep 17, 6:30AM CDT
The PGA TOUR and Astellas Pharma US, Inc. ("Astellas"), a U.S. subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503), will host their 17th Astellas Presents Executive Women's Day, a day-long forum focusing on professional, health-related and personal development discussions, at the 2013 TOUR Championship by Coca-Cola in Atlanta. The event is part of the PGA TOUR's Women's Initiative and is the final Executive Women's Day program in the 2013 season.
Humana Downgraded to Neutral - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 05, 4:05PM CDT
On Sep 4, 2013, we downgraded our recommendation on Humana Inc. to Neutral from Outperform.
Astellas and Merck Collaborate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 04, 4:00PM CDT
Astellas Pharma joined forces with Merck for the co-promotion of its SGLT2 inhibitor, ipragliflozin (ASP1941)
